Clinical Trial News and Research

RSS

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

17 Sep 2014

Milk consumption and dairy may lower blood pressure, CVD risk

Globally, cardiovascular disease (CVD) claims 17 million lives each year, while complications from high blood pressure take an additional 9.4 million. New research presented by international scientists at the 12th Euro Fed Lipid Congress in Montpellier, France on September 15, 2014, suggests that milk consumption and dairy may play a beneficial role.

17 Sep 2014

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

16 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

16 Sep 2014

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF).

16 Sep 2014

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.

16 Sep 2014

Early intervention prevents aggressive children from becoming violent, criminal adults

Aggressive children are less likely to become violent criminals or psychiatrically troubled adults if they receive early intervention, says a new study based on more than two decades of research.

16 Sep 2014

Osprey Medical to release enhanced AVERT Plus System at TCT Meeting

Osprey Medical Inc. has developed a new smart syringe and LCD display system, soon to be incorporated with its existing AVERT System.

16 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Assessing genetic variants can help identify men with increased risk of prostate cancer

Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease.

16 Sep 2014

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease.

16 Sep 2014

Complete analysis of the global mHealth market

With more than 7 Billion mobile network subscriptions worldwide, the mobile communications sector is rapidly gaining traction from a diverse range of vertical sectors. Healthcare is no exception to this trend.

15 Sep 2014

Four new styles of MENTOR MemoryShape Breast Implants get FDA approval

Mentor Worldwide LLC, the U.S. market leader in breast aesthetics, today announced the U.S. Food and Drug Administration has approved four additional styles of the MENTOR MemoryShape Breast Implants, expanding its suite of silicone breast implant products.

15 Sep 2014

Johns Hopkins Multiple Sclerosis Center receives MS research grant from Progressive Alliance

The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries by the International Progressive MS Alliance, a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis (MS).

15 Sep 2014

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

Loyola announces opening of new acupuncture clinic for patients with pelvic health disorders

Loyola University Health System will open an acupuncture clinic for men and women with pelvic health disorders this fall. The clinic will use acupuncture to treat patients with common conditions such as pelvic pain, nausea from pelvic surgery, interstitial cystitis, painful bladder syndrome, postoperative pain, prostatitis and overactive bladder.

11 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Clinical Trial News and Research

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Milk consumption and dairy may lower blood pressure, CVD risk

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Abbott announces initiation of ABSORB IV heart stent clinical trial

Early intervention prevents aggressive children from becoming violent, criminal adults

Osprey Medical to release enhanced AVERT Plus System at TCT Meeting

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Assessing genetic variants can help identify men with increased risk of prostate cancer

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

Complete analysis of the global mHealth market

Four new styles of MENTOR MemoryShape Breast Implants get FDA approval

Johns Hopkins Multiple Sclerosis Center receives MS research grant from Progressive Alliance

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Loyola announces opening of new acupuncture clinic for patients with pelvic health disorders

FDA approves Contrave extended-release tablets for chronic weight management

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer